Some time ago, my chiropractor friend told me Big Pharma elements would eventually buy up the small fry pioneers in the medical cannabis space. He was certain, by way of his contacts in conventional and alternative medicine, that mmj was high on the BP agenda because it could threaten their bottom line. BP would have to deal with mmj one way or another. When I look at the trading today, I wonder whether some big players, watching from the sidelines, are getting in.